Home / Market News / $TEM
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Tempus AI Receives IVDR Certification for xR RNA Sequencing Assay

Oct 26, 2026, 1:34 PM UTC · Primary ticker $TEM

Tempus AI announced its xR assay received Class C IVDR certification in the EU, validating its quality system for cancer genomic profiling. This regulatory approval is a positive step for the company's precision medicine offerings, potentially expanding its market reach in Europe.

Tempus AI's xR assay has achieved Class C IVDR certification in the European Union. This is a significant regulatory milestone as it validates the company's quality management system for its next-generation sequencing devices used in cancer genomic profiling. This certification allows Tempus AI to market and sell its xR assay in the EU, potentially expanding its revenue streams and market share in the precision medicine space. While not a major financial announcement, it represents a positive step in product commercialization and regulatory compliance, offering a long-term opportunity for growth in the European market for Tempus AI.

$TEM positive Regulatory approval for key product
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.